In situ breast carcinoma incidence statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub

Cases

New cases of in situ breast carcinoma each year, 2016-2018 average, UK.

 

Age

Peak rate of breast carcinoma in situ cases, 2015-2017, UK

 

Trend over time

Change in breast carcinoma in situ incidence rates since the early 1990s, UK

 

Breast carcinoma in situ incidence rates (European age-standardised (AS) rate Open a glossary item) for persons are significantly higher than the UK average in Wales and Northern Ireland, significantly lower than the UK average in Scotland and similar to the UK average in England. [1-4]

For breast cancinoma in situ, like most cancer types, differences between countries largely reflect risk factor prevalence in years past.

Breast Carcinoma in situ (D05), Average Number of New Cases Per Year, Crude and European Age-Standardised (AS) Incidence Rates per 100,000 Population, UK, 2016-2018

  England Scotland Wales Northern Ireland UK
Female Cases 7,092 492 450 271 8,306
Crude Rate 25.2 17.7 28.4 28.5 24.8
AS Rate 26.2 17.2 27.5 30.5 25.6
AS Rate - 95% LCL 25.8 16.3 26.0 28.4 25.2
AS Rate - 95% UCL 26.5 18.1 29.0 32.6 25.9
Male Cases 26 2 3 1 32
Crude Rate 0.1 0.1 0.2 0.1 0.1
AS Rate 0.1 0.1 0.2 0.1 0.1
AS Rate - 95% LCL 0.1 0.0 0.1 0.0 0.1
AS Rate - 95% UCL 0.1 0.1 0.3 0.2 0.1
Persons Cases 7,118 494 453 272 8,338
Crude Rate 12.8 9.1 14.5 14.5 12.6
AS Rate 13.5 9.0 14.3 15.8 13.2
AS Rate - 95% LCL 13.3 8.5 13.5 14.7 13.1
AS Rate - 95% UCL 13.7 9.5 15.0 16.9 13.4

95% LCL and 95% UCL are the 95% lower and upper confidence limits around the AS Rate Open a glossary item

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, July 2021. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2020. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were published by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales https://phw.nhs.wales/services-and-teams/welsh-cancer-intelligence-and-surveillance-unit-wcisu/cancer-incidence-in-wales-2002-2018/, March 2021.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2020. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2016-2018, ICD-10 D05.

Last reviewed:

Breast carcinoma in situ incidence is related to age, with the highest incidence rates being in the 65 to 69 age group. In the UK in 2015-2017, on average each year around a tenth of new cases (9%) were in people aged 75 and over.[1-4] This is a lower proportion of cases in older age groups compared with most cancers.

Age-specific incidence rates in females, rise steeply from around age 35-39, then decrease steeply from age 65-69 and decrease steadily from age 75-79. In males rates increase from age 35-39.The highest rates are in in the 65 to 69 age group for females and the 85 to 89 age group for males.

Incidence rates are significantly higher in females than males in a number of (mainly older) age groups.The gap is widest at age 45 to 49, when the age-specific incidence rate is 900 times higher in females than males.

Breast carcinoma in situ (D05), Average Number of New Cases per Year and Age-Specific Incidence Rates per 100,000 Population, UK, 2015-2017

For breast carcinoma in situ, most cases are identified through the breast screening programme. Incidence peaks first when routine screening starts at age 50, with a brief drop shortly after which reflects the diagnosis of prevalent cases at first-time screening. Incidence then falls rapidly when routine screening ends at age 70.

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2015-2017, D05.

Last reviewed:

Breast carcinoma in situ European age-standardised (AS) Open a glossary item incidence rates for females and males combined increased by 194% in the UK between 1993-1995 and 2015-2017.[1-4] The increase was larger in females than in males.

For females, breast carcinoma in situ AS incidence rates in the UK increased by 195% between 1993-1995 and 2015-2017. For males, breast carcinoma in situ AS incidence rates in the UK increased by 93% between 1993-1995 and 2015-2017.

Over the last decade in the UK (between 2005-2007 and 2015-2017), breast carcinoma in situ AS incidence rates for females and males combined increased by 33%.[1-4] In females AS incidence rates increased by 33%, and in males rates remained stable.

Breast Carcinoma In Situ (ICD-10 D05), European Age-Standardised Incidence Rates, UK, 1993-2017

Breast carcinoma in situ incidence rates have increased overall in all broad age groups in females in the UK since the early 1990s.[1-4] Rates in 0-24s have increased by 632%, in 25-49s have increased by 183%, in 50-64s have increased by 118%, in 65-69s have increased by 612%, in 70-79s have increased by 463%, and in 80+s have increased by 441%.

Breast Carcinoma In Situ (ICD-10 D05), European Age-Standardised Incidence Rates, By Age, Females, UK, 1993-2017

Breast carcinoma in situ incidence trends probably reflect the effective implementation of the UK breast screening programmes in the late 1980s, and subsequent extensions to the screening-eligible age group and improvements in screening methods – most cases are identified through the screening programme.[5] Changing prevalence of risk factors probably also plays a part.[5]

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  5. Glover JA, Bannon FJ, Hughes CM, et al. Increased diagnosis and detection rates of carcinoma in situ of the breast. Breast Cancer Res Treat. 2012;133(2):779-84 

About this data

Data is for UK, 1993-2017, ICD-10 D05.

Last reviewed:

Most in situ breast carcinoma cases are intraductal, and there is a much smaller proportion of lobular in situ breast carcinomas (2010-2012).[1-4]

A small proportion of cases did not have the specific part of the breast recorded in cancer registry data.[1-4]

Cases and percentages may not sum due to rounding

References

  1. Data were provided by the Office for National Statistics on request, July 2014. Similar data can be found here: http://www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations--england--series-mb1-/index.html.
  2. Data were provided by ISD Scotland on request, April 2014. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit on request, April 2014. Similar data can be found here: http://www.wales.nhs.uk/sites3/page.cfm?orgid=242&pid=59080.
  4. Data were provided by the Northern Ireland Cancer Registry on request, June 2014. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/CancerInformation/.

About this data

Data is for UK, 2010-2012, ICD-10 D05.

Last reviewed:

Breast carcinoma in situ incidence rates (European age-standardised (AS) rates Open a glossary item) in England in females are 28% lower in the most deprived quintile compared with the least, and in males are similar in the most deprived quintile compared with the least (2013-2017).[1]

It is estimated that there are around 900 fewer cases of breast carcinoma in situ each year in England in females than there would be if every deprivation quintile had the same age-specific crude incidence rates as the least deprived quintile.

Breast Carcinoma in situ (D05), Estimated Average Number of Fewer Cases per Year, by Deprivation Quintile, England, 2013-2017

Breast Carcinoma in situ (D05), European Age-Standardised Incidence Rates per 100,000 Population, by Deprivation Quintile, England, 2013-2017

No data are shown for males as the difference in age-standardised incidence rates between most and least deprived quintiles is not significant for males.

References

  1. Calculated by the Cancer Intelligence Team at Cancer Research UK, April 2020. Based on method reported in National Cancer Intelligence Network Cancer by Deprivation in England Incidence, 1996-2010 Mortality, 1997-2011 . Using cancer incidence data 2013-2017 (Public Health England) and population data 2013-2017 (Office for National Statistics) by Indices of Multiple Deprivation 2015 income domain quintile, cancer type, sex, and five-year age band.

About this data

Data is for England, 2013-2017, ICD-10 C21.

Last reviewed:

The proportion of incidence cases in White females with in situ breast carcinoma is significantly higher than for Asian or Black females.[1]

A similar ethnic profile is also reported for invasive breast cancer.[2]

Analysis included unknown data. For in situ breast carcinoma, 5,460 cases were identified; 28% had no known ethnicity.

References

  1. West Midlands Cancer Intelligence Unit. The Non-Invasive Breast Cancer report: An analysis of non-invasive breast cancers diagnosed in England from 1 January 2006 to 31 December 2007 (PDF 342KB). National Cancer Intelligence Unit, 2011. 
  2. National Cancer Intelligence Network (NCIN) and Cancer Research UK. Cancer Incidence and Survival by Major Ethnic Group, England, 2002-2006. London: NCIN; 2009.

About this data

Data is for England, 2006-2007, ICD-O2 & ICD-O3

Last reviewed:

An estimated 63,800 women who had been diagnosed with in situ breast carcinoma between 1991 and 2010 were alive in the UK at the end of 2010.[1]

References

  1. Macmillan Cancer Support and National Cancer Registration and Analysis Service. Cancer Prevalence UK Data Tables. London: NCRAS; 2015.

About this data

Data is for: Great Britain (1991-2010) and Northern Ireland (1993-2010), ICD-10 D05

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.